Literature DB >> 34979814

Chronic Acral Lesions ("COVID Toes"): To Add to Long Post- COVID-19 Syndrome?

Raphaël André1, Aurélie Hsieh1, Laurence T Trellu1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 34979814      PMCID: PMC9411688          DOI: 10.1177/00033197211068938

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.299


× No keyword cloud information.
Dear Editor, “COVID toes” are known to be associated with severe acute respiratory syndrome coronavirus (SARS-CoV-2) pathogenesis. Descriptions are concordant worldwide, however, follow-up is poorly described. Between February 2020 and April 2021, 4 cases lasting >3 months were followed-up in our dermatology clinic. The first patient was a 19-year-old woman without medical history. Two months after the onset of COVID-19 symptoms, chilblains-like acral lesions (CLAL) appeared on her toes (Figure 1). She complained of itching. There was no worsening with cold. SARS-CoV-2 serology was positive, and antinuclear antibodies, cryoglobulin, cryofibrinogen, cold agglutinin were negative. Chilblains-like acral lesions were still visible 4 months after onset. The second patient was an 18-year-old woman in good health. Two weeks after the onset of COVID-19, asymptomatic CLAL appeared on her toes and fingers. SARS-Cov-2 infection was confirmed by polymerase chain reaction (PCR). Moreover, she presented with a transient and painless urticarial eruption of the trunk, knees and hands exacerbated by heat and disappearing with cold. We found positive antinuclear antibodies with nucleolar fluorescence and rheumatoid factor, but there was no clinical systemic lupus sign. CLAL were still visible at 3 months. The third patient was a 60-year-old woman in good health. Soon after the onset of a COVID-19 with mild typical symptoms (anosmia), she presented painless CLAL of her toes. She did not performed any viral test. She noted an exacerbation by heat, but no worsening by cold. One digital necrosis was observed and CLAL remained for 5 months. The fourth case was a 20 year-old female who presented symptoms consistent with COVID-19 infection, but with a negative serology. Two months later, CLAL and erythromelalgia appeared on her toes and persisted after 10 months showing superficial necrotic evolution.
Figure 1.

Chilblain-like acral lesion on left foot.

Chilblain-like acral lesion on left foot. Our case series shows a CLAL duration of 3 to 10 months. Symptoms vary from no pain to functional disability. Cold was not a worsening factor, which differs from idiopathic chilblains. Necrotic evolution is possible as shown in 2 cases. Based on recent data, CLAL reflect an immunity against the virus by secretion of type 1 alpha-interferon.[2,3] Indeed, few patients with COVID toes have developed a severe form of the virus, and serologic or PCR test for SARS-Cov2 are sometimes negative. Among our 4 patients, 2 were positive, 1 negative and 1 not performed. Our data show a long duration of these symptoms but CLAL have not been integrated in the concept of “long COVID” (ie persistent complications), no pediatric acral acute syndrome had this duration. We suggest to add acute and chronic COVID toes as a separate post-infection entity.
  6 in total

1.  Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers.

Authors:  Sebastian Havervall; Axel Rosell; Mia Phillipson; Sara M Mangsbo; Peter Nilsson; Sophia Hober; Charlotte Thålin
Journal:  JAMA       Date:  2021-05-18       Impact factor: 56.272

2.  The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries.

Authors:  Esther E Freeman; Devon E McMahon; Jules B Lipoff; Misha Rosenbach; Carrie Kovarik; Seemal R Desai; Joanna Harp; Junko Takeshita; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Lindy P Fox
Journal:  J Am Acad Dermatol       Date:  2020-07-02       Impact factor: 11.527

Review 3.  Paraviral eruptions in the era of COVID-19: Do some skin manifestations point to a natural resistance to SARS-CoV-2?

Authors:  Dan Lipsker
Journal:  Clin Dermatol       Date:  2020-06-13       Impact factor: 3.541

4.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.

Authors:  Jérôme Hadjadj; Nader Yatim; Darragh Duffy; Frédéric Rieux-Laucat; Solen Kernéis; Benjamin Terrier; Laura Barnabei; Aurélien Corneau; Jeremy Boussier; Nikaïa Smith; Hélène Péré; Bruno Charbit; Vincent Bondet; Camille Chenevier-Gobeaux; Paul Breillat; Nicolas Carlier; Rémy Gauzit; Caroline Morbieu; Frédéric Pène; Nathalie Marin; Nicolas Roche; Tali-Anne Szwebel; Sarah H Merkling; Jean-Marc Treluyer; David Veyer; Luc Mouthon; Catherine Blanc; Pierre-Louis Tharaux; Flore Rozenberg; Alain Fischer
Journal:  Science       Date:  2020-07-13       Impact factor: 47.728

5.  Acute acral eruptions in children during the COVID-19 pandemic: Characteristics of 103 children and their family clusters.

Authors:  T Hubiche; A Phan; S Leducq; J Rapp; L Fertitta; H Aubert; S Barbarot; C Chiaverini; B Giraudeau; A Lasek; S Mallet; A Labarelle; M Piram; C McCuaig; L Martin; L Monitor; I Nicol; M Bissuel; A Bellissen; D Jullien; C Lesort; P Vabres; A Maruani
Journal:  Ann Dermatol Venereol       Date:  2021-01-09       Impact factor: 0.777

6.  Chilblains in children in the setting of COVID-19 pandemic.

Authors:  David Andina; Lucero Noguera-Morel; Marta Bascuas-Arribas; Jara Gaitero-Tristán; José Antonio Alonso-Cadenas; Silvia Escalada-Pellitero; Ángela Hernández-Martín; Mercedes de la Torre-Espi; Isabel Colmenero; Antonio Torrelo
Journal:  Pediatr Dermatol       Date:  2020-05-22       Impact factor: 1.997

  6 in total
  2 in total

1.  Histopathology of persistent long COVID toe: A case report.

Authors:  Michael S Nirenberg; Luis Requena; Carlos Santonja; Gregory T Smith; Steve A McClain
Journal:  J Cutan Pathol       Date:  2022-04-18       Impact factor: 1.458

Review 2.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.